194985-14-3Relevant academic research and scientific papers
Ng-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the n g-substituent?
Igel, Patrick,Schneider, Erich,Schnell, David,Elz, Sigurd,Seifert, Roland,Buschauer, Armin
supporting information; experimental part, p. 2623 - 2627 (2010/03/24)
3-(1H-Imidazol-4-yl)propylguanidine (SK&F 91486, 4) was identified as a potent partial agonist at the human histamine H3 receptor (hH3R) and human histamine H4 receptor (hH4R). With the aim to increase selectivity for the
Palladium- or iridium-catalyzed allylic substitution of guanidines: Convenient and direct modification of guanidines
Miyabe, Hideto,Yoshida, Kazumasa,Reddy, Valluru Krishna,Takemoto, Yoshiji
supporting information; experimental part, p. 305 - 311 (2009/04/07)
(Chemical Equation Presented) As a convenient and direct functionalization of guanidines, the transition metal-catalyzed allylic substitution of guanidines was studied. The guanidine derivatives bearing two electron-withdrawing substituents acted as react
Serine protease inhibitors
-
, (2008/06/13)
PCT No. PCT/EP97/00625 Sec. 371 Date Aug. 12, 1998 Sec. 102(e) Date Aug. 12, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/30073 PCT Pub. Date Aug. 21, 1997The invention relates to a compound having formula (I), wherein A, B, X, N, Z and Q are defined as
